Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Status Completed

Clinical Trial Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00889525
Study type	Interventional
Source	Seth Gordhandas Sunderdas Medical College
Contact
Status	Completed
Phase	Phase 3
Start date	November 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00881283` - Long-term Cardiovascular Risk in Cured Cushing's Patients
Completed	`NCT02568982` - Cushing's Disease Complications
Completed	`NCT02697734` - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease	Phase 3
Completed	`NCT01374906` - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Phase 3
Recruiting	`NCT03364803` - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting	`NCT02603653` - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease	N/A
Completed	`NCT01371565` - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Phase 3
Recruiting	`NCT00845351` - Preoperative Bexarotene Treatment for Cushing's Disease	Phase 1/Phase 2
Completed	`NCT02060383` - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Phase 4
Recruiting	`NCT03474601` - Seoul National University Pituitary Disease Cohort Study
Recruiting	`NCT04339751` - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	Phase 2
Not yet recruiting	`NCT04569591` - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease	N/A
Recruiting	`NCT02484755` - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Phase 2
Completed	`NCT01794793` - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Phase 4
Completed	`NCT00434148` - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Phase 3
Completed	`NCT03346954` - Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	N/A
Withdrawn	`NCT01925092` - Mifepristone in Children With Refractory Cushing's Disease	Phase 3
Completed	`NCT01582061` - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Phase 3
Recruiting	`NCT03708900` - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease	Phase 2
Terminated	`NCT00612066` - Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)	Phase 2